🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Cigna-Express Scripts deal gets U.S. antitrust approval

Published 17/09/2018, 21:36
© Reuters.  Cigna-Express Scripts deal gets U.S. antitrust approval
T
-
ESRX
-
CI
-
ELV
-
AET
-
HUM
-
CVS
-

By Caroline Humer

(Reuters) - Health insurer Cigna Corp's (N:CI) $52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co has passed U.S. antitrust scrutiny, the companies said on Monday, allowing them to proceed with a combination they say will lead to lower costs by better coordinating pharmacy and medical benefits.

The new company will marry Cigna's business of managing health plans for corporations and the government with Express Scripts' (O:ESRX) role handling pharmacy benefits for those same customers. Express Scripts also owns speciality pharmacies that distribute pricey drugs.

"We are pleased that the Department of Justice has cleared our transaction and that we are another step closer to completing our merger,” Cigna Chief Executive David Cordani said in a statement.

Wall Street analysts had expected the antitrust approval as the companies have little overlap in their businesses.

The decision may also bode well for the pending U.S. antitrust review of CVS Health Corp's (N:CVS) proposed $69 billion acquisition of health insurer Aetna Inc (N:AET).

“The Justice Department review of CVS’s planned purchase of Aetna is wrapping up and may conclude this month, but will take longer because of divestitures needed to resolve competitive concerns," a source familiar with the matter told Reuters.

The Justice Department in 2016 successfully blocked a pair of large health insurance mergers it believed would limit competition in the industry. Those were Aetna's plan to acquire smaller U.S. health insurer Humana Inc (N:HUM) for $37 billion, and a planned $54 billion combination of insurers Anthem Inc (N:ANTM) and Cigna.

Aetna and Cigna, however, were determined to seek growth through deals while responding to a changing healthcare landscape, eventually targeting mergers with the nation's largest pharmacy benefit managers (PBMs).

Antitrust experts have described those deals as vertical combinations that present fewer issues than the failed insurer mergers. That view was bolstered after the Justice Department lost its case to stop AT&T's (N:T) acquisition of media company Time Warner. It is appealing the decision.

Cigna and Express Scripts said they have already obtained clearances for the deal from departments of insurance in 16 states and are working with regulators in remaining jurisdictions to obtain clearance for the merger.

They continue to expect the deal to close by the end of the year, subject to the satisfaction of all closing conditions.

Cigna shares closed up 1.4 percent. Express Scripts shares closed up 3.7 percent.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.